A randomized controlled trial of two diets enriched with protein or fat in patients with type 2 diabetes treated with dapagliflozin

Abstract Sodium-glucose cotranspsorter-2 (SGLT2) inhibitors (SGLT2i) involve loss of skeletal muscle mass, potentially leading to inadequate HbA1c reduction in type 2 diabetes (T2DM), since muscle mass is related to insulin sensitivity. The benefit of protein-enriched diet for improving HbA1c in SGL...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yasuhiro Watanabe, Daisuke Suzuki, Nobuichi Kuribayashi, Daigaku Uchida, Mitsutoshi Kato, Hiroshi Ohashi, Daiji Nagayama, Takashi Yamaguchi, Masahiro Ohira, Atsuhito Saiki, Ichiro Tatsuno
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/5793f965b8194c63ae146dc8b9d83405
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5793f965b8194c63ae146dc8b9d83405
record_format	dspace
spelling	oai:doaj.org-article:5793f965b8194c63ae146dc8b9d834052021-12-02T17:51:06ZA randomized controlled trial of two diets enriched with protein or fat in patients with type 2 diabetes treated with dapagliflozin10.1038/s41598-021-90879-z2045-2322https://doaj.org/article/5793f965b8194c63ae146dc8b9d834052021-05-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-90879-zhttps://doaj.org/toc/2045-2322Abstract Sodium-glucose cotranspsorter-2 (SGLT2) inhibitors (SGLT2i) involve loss of skeletal muscle mass, potentially leading to inadequate HbA1c reduction in type 2 diabetes (T2DM), since muscle mass is related to insulin sensitivity. The benefit of protein-enriched diet for improving HbA1c in SGLT2i-treated T2DM patients remains unclear. We conducted a multicenter, double-blind, randomized, controlled, investigator-initiated clinical trial. 130 T2DM patients treated with dapagliflozin (5 mg) were randomized to isoenergic protein-rich formula diet (P-FD) or fat-rich FD (F-FD) (1:1 allocation) to replace one of three meals/day for 24 weeks. Primary outcome was change in HbA1c. Secondary outcomes were changes in serum insulin, body composition and other metabolic parameters. Although HbA1c decreased significantly in both groups [mean (95% confidence interval) − 0.7% (− 0.9 to − 0.5) in P-FD, − 0.6% (− 0.8 to − 0.5) in F-FD], change in HbA1c was not significantly different between the two groups (P = 0.4474). Fasting insulin and body fat mass decreased, while HDL-cholesterol increased significantly in P-FD, and these changes were significantly greater compared with F-FD (all, P < 0.05). In T2DM treated with dapagliflozin, protein-enriched diet does not contribute to HbA1c reduction, although it decreases serum insulin and body fat mass, and increases HDL-cholesterol compared with fat-enriched diet with identical calories and carbohydrate ratio.Yasuhiro WatanabeDaisuke SuzukiNobuichi KuribayashiDaigaku UchidaMitsutoshi KatoHiroshi OhashiDaiji NagayamaTakashi YamaguchiMasahiro OhiraAtsuhito SaikiIchiro TatsunoNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Yasuhiro Watanabe Daisuke Suzuki Nobuichi Kuribayashi Daigaku Uchida Mitsutoshi Kato Hiroshi Ohashi Daiji Nagayama Takashi Yamaguchi Masahiro Ohira Atsuhito Saiki Ichiro Tatsuno A randomized controlled trial of two diets enriched with protein or fat in patients with type 2 diabetes treated with dapagliflozin
description	Abstract Sodium-glucose cotranspsorter-2 (SGLT2) inhibitors (SGLT2i) involve loss of skeletal muscle mass, potentially leading to inadequate HbA1c reduction in type 2 diabetes (T2DM), since muscle mass is related to insulin sensitivity. The benefit of protein-enriched diet for improving HbA1c in SGLT2i-treated T2DM patients remains unclear. We conducted a multicenter, double-blind, randomized, controlled, investigator-initiated clinical trial. 130 T2DM patients treated with dapagliflozin (5 mg) were randomized to isoenergic protein-rich formula diet (P-FD) or fat-rich FD (F-FD) (1:1 allocation) to replace one of three meals/day for 24 weeks. Primary outcome was change in HbA1c. Secondary outcomes were changes in serum insulin, body composition and other metabolic parameters. Although HbA1c decreased significantly in both groups [mean (95% confidence interval) − 0.7% (− 0.9 to − 0.5) in P-FD, − 0.6% (− 0.8 to − 0.5) in F-FD], change in HbA1c was not significantly different between the two groups (P = 0.4474). Fasting insulin and body fat mass decreased, while HDL-cholesterol increased significantly in P-FD, and these changes were significantly greater compared with F-FD (all, P < 0.05). In T2DM treated with dapagliflozin, protein-enriched diet does not contribute to HbA1c reduction, although it decreases serum insulin and body fat mass, and increases HDL-cholesterol compared with fat-enriched diet with identical calories and carbohydrate ratio.
format	article
author	Yasuhiro Watanabe Daisuke Suzuki Nobuichi Kuribayashi Daigaku Uchida Mitsutoshi Kato Hiroshi Ohashi Daiji Nagayama Takashi Yamaguchi Masahiro Ohira Atsuhito Saiki Ichiro Tatsuno
author_facet	Yasuhiro Watanabe Daisuke Suzuki Nobuichi Kuribayashi Daigaku Uchida Mitsutoshi Kato Hiroshi Ohashi Daiji Nagayama Takashi Yamaguchi Masahiro Ohira Atsuhito Saiki Ichiro Tatsuno
author_sort	Yasuhiro Watanabe
title	A randomized controlled trial of two diets enriched with protein or fat in patients with type 2 diabetes treated with dapagliflozin
title_short	A randomized controlled trial of two diets enriched with protein or fat in patients with type 2 diabetes treated with dapagliflozin
title_full	A randomized controlled trial of two diets enriched with protein or fat in patients with type 2 diabetes treated with dapagliflozin
title_fullStr	A randomized controlled trial of two diets enriched with protein or fat in patients with type 2 diabetes treated with dapagliflozin
title_full_unstemmed	A randomized controlled trial of two diets enriched with protein or fat in patients with type 2 diabetes treated with dapagliflozin
title_sort	randomized controlled trial of two diets enriched with protein or fat in patients with type 2 diabetes treated with dapagliflozin
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/5793f965b8194c63ae146dc8b9d83405
work_keys_str_mv	AT yasuhirowatanabe arandomizedcontrolledtrialoftwodietsenrichedwithproteinorfatinpatientswithtype2diabetestreatedwithdapagliflozin AT daisukesuzuki arandomizedcontrolledtrialoftwodietsenrichedwithproteinorfatinpatientswithtype2diabetestreatedwithdapagliflozin AT nobuichikuribayashi arandomizedcontrolledtrialoftwodietsenrichedwithproteinorfatinpatientswithtype2diabetestreatedwithdapagliflozin AT daigakuuchida arandomizedcontrolledtrialoftwodietsenrichedwithproteinorfatinpatientswithtype2diabetestreatedwithdapagliflozin AT mitsutoshikato arandomizedcontrolledtrialoftwodietsenrichedwithproteinorfatinpatientswithtype2diabetestreatedwithdapagliflozin AT hiroshiohashi arandomizedcontrolledtrialoftwodietsenrichedwithproteinorfatinpatientswithtype2diabetestreatedwithdapagliflozin AT daijinagayama arandomizedcontrolledtrialoftwodietsenrichedwithproteinorfatinpatientswithtype2diabetestreatedwithdapagliflozin AT takashiyamaguchi arandomizedcontrolledtrialoftwodietsenrichedwithproteinorfatinpatientswithtype2diabetestreatedwithdapagliflozin AT masahiroohira arandomizedcontrolledtrialoftwodietsenrichedwithproteinorfatinpatientswithtype2diabetestreatedwithdapagliflozin AT atsuhitosaiki arandomizedcontrolledtrialoftwodietsenrichedwithproteinorfatinpatientswithtype2diabetestreatedwithdapagliflozin AT ichirotatsuno arandomizedcontrolledtrialoftwodietsenrichedwithproteinorfatinpatientswithtype2diabetestreatedwithdapagliflozin AT yasuhirowatanabe randomizedcontrolledtrialoftwodietsenrichedwithproteinorfatinpatientswithtype2diabetestreatedwithdapagliflozin AT daisukesuzuki randomizedcontrolledtrialoftwodietsenrichedwithproteinorfatinpatientswithtype2diabetestreatedwithdapagliflozin AT nobuichikuribayashi randomizedcontrolledtrialoftwodietsenrichedwithproteinorfatinpatientswithtype2diabetestreatedwithdapagliflozin AT daigakuuchida randomizedcontrolledtrialoftwodietsenrichedwithproteinorfatinpatientswithtype2diabetestreatedwithdapagliflozin AT mitsutoshikato randomizedcontrolledtrialoftwodietsenrichedwithproteinorfatinpatientswithtype2diabetestreatedwithdapagliflozin AT hiroshiohashi randomizedcontrolledtrialoftwodietsenrichedwithproteinorfatinpatientswithtype2diabetestreatedwithdapagliflozin AT daijinagayama randomizedcontrolledtrialoftwodietsenrichedwithproteinorfatinpatientswithtype2diabetestreatedwithdapagliflozin AT takashiyamaguchi randomizedcontrolledtrialoftwodietsenrichedwithproteinorfatinpatientswithtype2diabetestreatedwithdapagliflozin AT masahiroohira randomizedcontrolledtrialoftwodietsenrichedwithproteinorfatinpatientswithtype2diabetestreatedwithdapagliflozin AT atsuhitosaiki randomizedcontrolledtrialoftwodietsenrichedwithproteinorfatinpatientswithtype2diabetestreatedwithdapagliflozin AT ichirotatsuno randomizedcontrolledtrialoftwodietsenrichedwithproteinorfatinpatientswithtype2diabetestreatedwithdapagliflozin
_version_	1718379286239379456

A randomized controlled trial of two diets enriched with protein or fat in patients with type 2 diabetes treated with dapagliflozin

Ejemplares similares